ArticleDiscover oncology2026
HSPA8 is a biomarker associated with prognosis and immunity in skin cutaneous melanoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundSkin cutaneous melanoma (SKCM) is a highly invasive malignant tumor with poor prognosis in the advanced stage and prominent problems of immunotherapy resistance. Heat shock protein A8 (HSPA8) is involved in tumor progression and immune escape in various cancers, but its role in SKCM remains unclear. This study aimed to explore the role of HSPA8 in SKCM.
methodsBased on the SKCM transcriptome, clinical data, and related biological information from public databases including The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Human Protein Atlas (HPA), and cGSCALite platform, we used differential analysis, survival analysis, receiver operating characteristic curve (ROC), Cox regression, functional enrichment analysis, immunological correlation analysis, and molecular docking to systematically evaluate the biological role of HSPA8 in SKCM.
resultsHSPA8 was highly expressed in SKCM tissues compared with normal tissues, and exhibited significant diagnostic efficacy for SKCM. Multivariate Cox regression analysis confirmed that HSPA8 was an independent risk factor closely related to the poor prognosis of SKCM patients. Functional enrichment analysis showed that HSPA8-related genes were mainly enriched in tumor-related pathways such as cytokine-cytokine receptor interaction and TGF-β signaling pathway. Immunological correlation analysis revealed that HSPA8 was closely associated with the construction of an immunosuppressive microenvironment in SKCM. In addition, drug sensitivity analysis and molecular docking showed potential sensitivity to GSK-J4 and Nutlin-3a(-) based on in silico prediction.
conclusionHSPA8 is a biomarker related to the prognosis and immunity of SKCM, which may promote tumor progression by regulating the immunosuppressive microenvironment. This study clarifies the biological role of HSPA8 in SKCM and provides a new target and theoretical basis for the precision diagnosis and immunotherapy of SKCM.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.